SCHEMBL28890960

SCHEMBL28890960

CCNC(=O)c1cnc(N2CCCC2CO)nc1NCc1ccc(OC)c(Cl)c1

nearest known ligand 0.85

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 9/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28890959 1.00 PDE5A (0.85) PDE5A
SCHEMBL8499754 0.95 PDE5A (0.89) PDE5A
SCHEMBL8486537 0.92 PDE5A (0.83) PDE5A
SCHEMBL28412519 0.92 PDE5A (0.83) PDE5A
SCHEMBL20832907 0.92 PDE5A (0.85) PDE5A
SCHEMBL28415169 0.92 PDE5A (0.81) PDE5A
SCHEMBL28415166 0.92 PDE5A (0.81) PDE5A
SCHEMBL8487823 0.92 PDE5A (0.81) PDE5A
Avanafil SCHEMBL118799 0.91 PDE5A (1.00) PDE5A
Avanafil SCHEMBL16377474 0.91 PDE5A (1.00) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111297868-A Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases 黄泳华 2020-06-19 CN claimed
CN-111297868-A Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases 黄泳华 2020-06-19 CN disclosed